Orforglipron

Category: Small molecules · Last updated 2026-05-19

Orforglipron (LY3502970) is an orally bioavailable non-peptide small-molecule agonist of the GLP-1 receptor developed by Eli Lilly. Unlike injectable GLP-1 analogs such as semaglutide and tirzepatide, orforglipron is a small molecule taken once daily by mouth without dietary restriction.

Peppudex card: see the mechanism + evidence-grade summary at [Peppudex / Orforglipron](https://peppudex.com/peptides/orforglipron).

Overview

Until orforglipron, every clinically validated GLP-1 receptor agonist was a peptide that required subcutaneous injection (or, in the case of oral semaglutide, a specialized absorption-enhancer formulation taken on an empty stomach). Orforglipron is structurally distinct · a small molecule that binds an allosteric site on the GLP-1 receptor and triggers downstream Gs/cAMP signaling without the absorption and stability constraints that limit oral peptide delivery.

Mechanism

Orforglipron is a positive allosteric modulator of the GLP-1 receptor. The compound binds outside the orthosteric peptide-binding pocket and stabilizes the active receptor conformation, producing functional agonist activity. Downstream signaling is similar to peptide GLP-1 agonists · insulin secretion, satiety, slowed gastric emptying.

See: GLP-1_receptor, Incretin_effect.

Evidence

Clinical data through Phase 2 and into Phase 3:

Phase 2 obesity (NCT05051579) · 36-week trial in adults with obesity reported up to ~14.7% placebo-subtracted weight loss at 45 mg daily (Wharton et al., NEJM 2023; PMID 37364188).
Phase 2 type 2 diabetes · HbA1c reduction up to ~2.1% (Frias et al., NEJM 2023).
Phase 3 ACHIEVE-1 / ATTAIN-1 · large Phase 3 obesity and T2D programs enrolling.

The Phase 2 efficacy is comparable to first-generation injectable GLP-1 agonists, with the convenience advantage of once-daily oral dosing without dietary restriction.

Pharmacokinetics

Orforglipron has an oral half-life of approximately 29 to 49 hours, supporting once-daily dosing. Unlike oral semaglutide (which requires fasted administration with a SNAC absorption enhancer), orforglipron has no dietary restriction. Steady state is reached in 8 to 10 days. The molecule is metabolized primarily via CYP3A4 with biliary elimination.

Dosing literature

Phase 2 trials used daily doses of 12 mg to 45 mg administered orally. The wiki does not recommend any human dose; orforglipron is investigational and not FDA-approved as of 2026-05.

Storage

As a small molecule, orforglipron does not require cold-chain storage. Standard tablet storage at room temperature is expected for the commercial formulation.

Regulatory status

United States. Investigational. Not yet FDA-approved as of 2026-05.
WADA. Not listed on the 2024 Prohibited List.

Side effects (per published Phase 2)

Adverse-event profile mirrors injectable GLP-1 agonists: dose-dependent nausea, vomiting, diarrhea, constipation, decreased appetite. Most events were mild-to-moderate and concentrated in the titration period. Pancreatitis class-warning applies. Class-based contraindications for medullary thyroid carcinoma (MTC) and MEN-2 are expected to apply if approved.

References

Wharton S, et al. "Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity." N Engl J Med. 2023;389(10):877-888. PMID 37364188.
Frias JP, et al. "Efficacy and safety of oral orforglipron in patients with type 2 diabetes." N Engl J Med. 2023;389(10):868-877.

Research framing only. Peppu Wiki documents the published research literature surrounding peptide compounds. Articles describe in-vitro and animal-model evidence, regulatory status, and community-reported protocols. Nothing on this site is medical advice, a recommendation for human use, or a substitute for consultation with a qualified clinician. All compounds discussed are research-use only. Citations should be verified at the source before relying on any quantitative claim.

View edit history of this page